Evidence map›Paper›PMID 34609660›Full record

Observational studyNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2022

Fabry-Stroke Italian Registry (FSIR): a nationwide, prospective, observational study about incidence and characteristics of Fabry-related stroke in young-adults. Presentation of the study protocol.

Ilaria Romani, Patrizia Nencini, Cristina Sarti, Giovanni Pracucci, Marialuisa Zedde, Antonia Nucera, Vittoria Cianci, Jessica Moller, Danilo Toni, Daniele Orsucci and 29 more

Registry-linked trialOpen access · hybridAbstract readObservational Study
In one paragraph

Observational study in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06935578 (RAre, But Not aLone), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06935578 recruitingnot on this mapstarted 2023, after this paper: background citation

RAre, But Not aLone: a Large Italian Network to Empower the Impervious diaGNostic Pathway of Rare cerEbrovascular Diseases (ALIGNED)

TypeobservationalSponsorFondazione I.R.C.C.S. Istituto Neurologico Carlo BestaRan2023 to 2026Enrolled500ConditionsCADASIL, CADASIL (Diagnosis), Moya Moya Disease, Moyamoya
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors at 20 institutions in 1 country.

Ilaria RomaniDepartment of Neurosciences, Psychology, Pharmacology, and Child Health (NEUROFARBA), University of Florence, Florence, Italy. ilaria.romani@unifi.it.ORCID http://orcid.org/0000-0001-7966-3525
Patrizia NenciniStroke Unit, Careggi University Hospital, Firenze, Italy.
Cristina SartiDepartment of Neurosciences, Psychology, Pharmacology, and Child Health (NEUROFARBA), University of Florence, Florence, Italy.
Giovanni PracucciDepartment of Neurosciences, Psychology, Pharmacology, and Child Health (NEUROFARBA), University of Florence, Florence, Italy.
Marialuisa ZeddeNeurology, S. Maria Nuova Hospital, Reggio Emilia, Italy.
Antonia NuceraNeurovascular Treatment Unit, Spaziani Hospital, Frosinone, Italy.
Vittoria CianciNeurology, Bianchi-Melacrino-Morelli Hospital, Reggio Calabria, Italy.
Jessica MollerNeurology-Stroke Unit, Brotzu Hospital, Cagliari, Italy.
Danilo ToniEmergency Department Stroke Unit, Umberto I Polyclinic Hospital, Sapienza University of Rome, Rome, Italy.
Daniele OrsucciNeurology, Lucca Hospital, Lucca, Italy.
Carmela CasellaStroke Unit, Department of Clinical and Experimental Medicine, AOU Policlinico G. Martino, University of Messina, Messina, Italy.
Vincenza PintoNeurology and Stroke Unit, Di Summa - Perrino Hospital, Brindisi, Italy.
Pasquale PalumboNeurology, Neurophysiopathology, and Stroke Unit, Santo Stefano Hospital, Prato, Italy.
Leonardo BarbariniStroke Unit, Fazzi Hospital, Lecce, Italy.
Rita BellaAcute Cerebrovascular Diseases Unit, Vittorio Emanuele University Hospital, Catania, Italy.
Michele RagnoDivision of Neurology, C. e G. Mazzoni Hospital and Madonna del Soccorso Hospital, Ascoli Piceno, Italy.
Umberto ScodittiNeurology - Stroke Care Program, Parma University Hospital, Parma, Italy.
Domenico Maria MezzapesaUniversity Neurology, Bari Polyclinic Hospital, Bari, Italy.
Rossana TassiNeurosonology and Stroke Unit, Siena University Hospital, Siena, Italy.
Marina DiomediNeurovascular Treatment Unit, Tor Vergata Polyclinic Hospital, Rome, Italy.
Anna CavalliniStroke Unit, C. Mondino Foundation, Pavia, Italy.
Gino VolpiNeurology, San Iacopo Hospital, Pistoia, Italy.
Alberto ChitiNeurology, Apuane Hospital, Massa e Carrara, Italy.
Guido BigliardiStroke Unit, Sant'Agostino Estense New Hospital, Modena, Italy.
Simona SaccoNeurology and Stroke Unit, SS Filippo e Nicola Hospital , Avezzano, Italy.
Giovanni LinoliNeurology, San Donato Hospital, Arezzo, Italy.
Stefano RicciStroke Center - Neurology, Città Di Castello Hospital and Gubbio-Gualdo Tadino Hospital, Città di Castello, Italy.
Antonello GiordanoNeurology, Guzzardi Hospital, Ragusa, Italy.
Bruno BonettiStroke Unit, Verona University Hospital, Verona, Italy.
Maurizia RasuraNeurology, Sant'Andrea Hospital, Rome, Italy.
Emanuela CecconiNeurovascular Treatment Unit, Belcolle Hospital, Viterbo, Italy.
Lucia Princiotta CariddiNeurology, Circolo University Hospital, Varese, Italy.
Roberto Currò DossiStroke Unit, Bolzano Hospital, Bolzano, Italy.
Marta MelisNeurology, Monserrato University Hospital, Cagliari, Italy.
Domenico ConsoliNeurology, Jazzolino Hospital, Vibo Valentia, Italy.
Donata GuidettiNeurology, Da Saliceto Hospital, Piacenza, Italy.
Silvia BiaginiDepartment of Neurosciences, Psychology, Pharmacology, and Child Health (NEUROFARBA), University of Florence, Florence, Italy.
Donatella AccavoneDepartment of Neurosciences, Psychology, Pharmacology, and Child Health (NEUROFARBA), University of Florence, Florence, Italy.
Domenico InzitariDepartment of Neurosciences, Psychology, Pharmacology, and Child Health (NEUROFARBA), University of Florence, Florence, Italy.
University of Florence · ITAzienda ospedaliera "Bianchi-Melacrino-Morelli" · ITAzienda Ospedaliera G. Brotzu · ITAzienda Ospedaliero-Universitaria Careggi · ITAzienda Ospedaliero-Universitaria Policlinico - Vittorio Emanuele · ITAzienda Unita' Sanitaria Locale Di Modena · ITCittà di Castello Hospital · ITCTO Andrea Alesini · ITGuglielmo da Saliceto Hospital · ITIMT School for Advanced Studies Lucca · ITOspedale A. Perrino · ITOspedale di Belcolle · ITOspedale di Bolzano · ITOspedale San Donato · ITOspedale San Filippo Neri · ITOspedale Vito Fazzi · ITPoliclinico Tor Vergata · ITPoliclinico Umberto I · ITSanta Maria Nuova Hospital · ITUniversity of Cagliari · IT

Funding

Takeda Pharmaceutical Company IIR-ITA-00977
6 · The paper itself

Abstract

backgroundTIA and stroke, both ischemic and hemorrhagic, may complicate Fabry disease at young-adult age and be the first manifestation that comes to the clinician's attention. No definite indications have yet been elaborated to guide neurologists in Fabry disease diagnostics. In current practice, it is usually sought in case of cryptogenic strokes (while Fabry-related strokes can also occur by classical pathogenic mechanisms) or through screening programs in young cerebrovascular populations. Data on recurrence and secondary prevention of Fabry's stroke are scanty.

methodsThe study had a prospective observational design involving 33 Italian neurological Stroke Units. Considering the incidence of TIA/stroke in the European population aged < 60 years and the frequency of Fabry disease in this category (as foreseen by a pilot study held at the Careggi University-Hospital, Florence), we planned to screen for Fabry disease a total of 1740 < 60-year-old individuals hospitalized for TIA, ischemic, or hemorrhagic stroke. We investigated TIA and stroke pathogenesis through internationally validated scales and we gathered information on possible early signs of Fabry disease among all cerebrovascular patients. Every patient was tested for Fabry disease through dried blood spot analysis. Patients who received Fabry disease diagnosis underwent a 12-month follow-up to monitor stroke recurrence and multi-system progression after the cerebrovascular event. DISCUSSION: The potential implications of this study are as follows: (i) to add information about the yield of systematic screening for Fabry disease in a prospective large cohort of acute cerebrovascular patients; (ii) to deepen knowledge of clinical, pathophysiological, and prognostic characteristics of Fabry-related stroke.

Indexed as

Ischemic Attack, TransientStrokeAdultHumansIncidenceItalyMiddle AgedProspective StudiesRegistriesFabry diseaseGenetic disordersIntracerebral hemorrhageIschemic strokePreventionTIA

Identifiers

PMID34609660
PMCPMC8918192
OpenAlexW3202434691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.